drugset / Trial / NCT01177319
Glutathione (GSH) In The Treatment of Parkinson's Disease
Phase 2
Completed
20 enrolled
University of South Florida
Wellness Health & Pharmaceuticals, Inc. · collab
RandomizedCrossoverTriple-blindTreatment
Summary
This is an investigator initiated pilot study to examine the effects of GSH in PD. The goal of this study is to acquire some basic data regarding side effects and efficacy of this compound to determine if this is a possible treatment option that could be recommended to interested PD patients.
Timeline
- Start
- 2003-09
- Primary completion
- 2007-03
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glutathione | Peptide | 1400 mg | Intravenous |